BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 20425334)

  • 1. Hydroxyurea: The drug of choice for polycythemia vera and essential thrombocythemia.
    Dingli D; Tefferi A
    Curr Hematol Malig Rep; 2006 Jun; 1(2):69-74. PubMed ID: 20425334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of the myeloproliferative disorders with 32P.
    Berlin NI
    Eur J Haematol; 2000 Jul; 65(1):1-7. PubMed ID: 10914933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
    Nand S; Stock W; Godwin J; Fisher SG
    Am J Hematol; 1996 May; 52(1):42-6. PubMed ID: 8638610
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea.
    Alvarez-Larrán A; Martínez-Avilés L; Hernández-Boluda JC; Ferrer-Marín F; Antelo ML; Burgaleta C; Mata MI; Xicoy B; Martínez-Trillos A; Gómez-Casares MT; Durán MA; Marcote B; Ancochea A; Senín A; Angona A; Gómez M; Vicente V; Cervantes F; Bellosillo B; Besses C
    Ann Hematol; 2014 Dec; 93(12):2037-43. PubMed ID: 24981691
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of polycythaemia vera and essential thrombocythaemia.
    Tefferi A; Silverstein MN
    Baillieres Clin Haematol; 1998 Dec; 11(4):769-85. PubMed ID: 10640216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management.
    Tefferi A
    Am J Hematol; 2012 Mar; 87(3):285-93. PubMed ID: 22331582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Efficacious treatment of a fatal blood disease: polycythemia vera].
    Sánchez Fayos J; Román Barbero A; Nevado Reviriego I
    Sangre (Barc); 1997 Jun; 42(3):215-8. PubMed ID: 9381264
    [No Abstract]   [Full Text] [Related]  

  • 8. [Essential thrombocythemia: conventional therapy].
    Grossi A; Vannucchi AM; Longo G; Rafanelli D; Rossi Ferrini P
    Haematologica; 1991 Jun; 76 Suppl 3():368-70. PubMed ID: 1752534
    [No Abstract]   [Full Text] [Related]  

  • 9. Prevention of thrombosis in polycythemia vera and essential thrombocythemia.
    Landolfi R; Di Gennaro L
    Haematologica; 2008 Mar; 93(3):331-5. PubMed ID: 18310537
    [No Abstract]   [Full Text] [Related]  

  • 10. Leukemic transformation in myeloproliferative neoplasms: therapy-related or unrelated?
    Björkholm M; Hultcrantz M; Derolf ÅR
    Best Pract Res Clin Haematol; 2014 Jun; 27(2):141-53. PubMed ID: 25189725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic options for essential thrombocythemia and polycythemia vera.
    Solberg LA
    Semin Oncol; 2002 Jun; 29(3 Suppl 10):10-5. PubMed ID: 12096352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of thrombotic and hemorrhagic events during polycythemia vera or essential thrombocythemia based on leukocyte burden.
    Lim Y; Lee JO; Kim SH; Kim JW; Kim YJ; Lee KW; Lee JS; Bang SM
    Thromb Res; 2015 May; 135(5):846-51. PubMed ID: 25743883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia.
    Kiladjian JJ; Rain JD; Bernard JF; Briere J; Chomienne C; Fenaux P
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):417-21. PubMed ID: 16810617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of polycythemia vera: use of 32P alone or in combination with maintenance therapy using hydroxyurea in 461 patients greater than 65 years of age. The French Polycythemia Study Group.
    Najean Y; Rain JD
    Blood; 1997 Apr; 89(7):2319-27. PubMed ID: 9116275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols.
    Berk PD; Goldberg JD; Donovan PB; Fruchtman SM; Berlin NI; Wasserman LR
    Semin Hematol; 1986 Apr; 23(2):132-43. PubMed ID: 3704665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Busulfan versus hydroxyurea in the treatment of polycythemia vera (PV) and essential thrombocythemia (ET).
    Brodsky I
    Am J Clin Oncol; 1998 Feb; 21(1):105-6. PubMed ID: 9499248
    [No Abstract]   [Full Text] [Related]  

  • 17. JAK2V617F mutation and hydroxyurea treatment as determinants of immature platelet parameters in essential thrombocythemia and polycythemia vera patients.
    Panova-Noeva M; Marchetti M; Buoro S; Russo L; Leuzzi A; Finazzi G; Rambaldi A; Ottomano C; Ten Cate H; Falanga A
    Blood; 2011 Sep; 118(9):2599-601. PubMed ID: 21750318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contemporary approach to essential thrombocythemia and polycythemia vera.
    Aruch D; Mascarenhas J
    Curr Opin Hematol; 2016 Mar; 23(2):150-60. PubMed ID: 26717193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is hydroxyurea leukemogenic in essential thrombocythemia?
    Tefferi A
    Blood; 1998 Aug; 92(4):1459-60; author reply 1460-1. PubMed ID: 9694740
    [No Abstract]   [Full Text] [Related]  

  • 20. Therapy for polycythemia vera and essential thrombocythemia is driven by the cardiovascular risk.
    Barbui T; Finazzi G
    Semin Thromb Hemost; 2007 Jun; 33(4):321-9. PubMed ID: 17525889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.